ILMN

Business Context and Reporting Period

Company: Illumina, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended January 1, 2006 (52 weeks)
Business Overview: Illumina develops and markets next-generation tools for the large-scale analysis of genetic variation and function, primarily focusing on SNP genotyping and gene expression profiling. Key technologies include BeadArray and Oligator. The company operates in a single business segment.

Key Financial Metrics

Gross Margins: Product revenue gross margin was 66% (down from 71% in 2005). Service and other revenue gross margin was 77% (down from 79% in 2005).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 45% to $73.5 million, driven by a 43% increase in product revenue (BeadStation, consumables, and oligo sales) and a 73% increase in service revenue (SNP genotyping contracts and milestone payments).
• Net Loss Expansion: Net loss widened significantly to $20.9 million from $6.2 million. This was primarily due to a one-time $15.8 million charge for acquired in-process research and development (IPR&D) related to the CyVera Corporation acquisition.
• Acquisition: Completed the acquisition of CyVera Corporation in April 2005 for approximately $17.8 million. $15.8 million was expensed immediately as IPR&D.
• Collaboration: Recognized $1.1 million in milestone revenue from the strategic collaboration with Invitrogen Corporation.
• Legal Settlements: Paid $5.9 million in January 2005 to settle a termination-of-employment lawsuit, removing the liability from the balance sheet. No litigation judgment expense was recorded in 2006.

Guidance, Outlook, and Risks

• Outlook: Management expects research and development expenses to increase in absolute dollars in 2006 but decrease as a percentage of revenue. Selling, general, and administrative expenses are expected to accelerate due to sales force expansion.
• Accounting Changes: The company adopted SFAS No. 123R (Share-Based Payment) effective January 2, 2006. This is expected to add $9.0 million to $12.0 million in non-cash operating expenses in 2006, potentially impacting reported profitability.
• Key Risks:
  • Intellectual Property Litigation: Ongoing patent infringement lawsuit filed by Affymetrix, Inc. in July 2004. Trial is scheduled for October 2006. An unfavorable outcome could block product sales or require significant damages.
  • Profitability: The company has incurred net losses since inception. Continued profitability depends on revenue growth outpacing significant increases in operating expenses.
  • Market Acceptance: Success depends on the adoption of new technologies (BeadArray, Oligator) and the growth of emerging markets for genetic analysis.
  • Concentration: Approximately 38% of revenue is derived from international customers, exposing the company to currency and geopolitical risks.

Investor Verification Checklist

• Cash Runway: Verify if the $50.8 million cash balance is sufficient to fund operations through 2006 given the expected increase in expenses and the adoption of SFAS 123R.
• IP Litigation Status: Monitor the progress of the Affymetrix lawsuit, as an injunction could materially harm the business.
• Product Mix Impact: Assess the sustainability of gross margins given the shift toward lower-margin instrumentation sales and the impact of the Invitrogen collaboration on oligo margins.
• CyVera Integration: Track the commercialization timeline for CyVera's digital-microbead technology, with first products expected in the second half of 2006.
• Stock-Based Compensation: Review the actual impact of SFAS 123R adoption on the 2006 income statement once the first quarterly report is filed.